Abstract Objective Antiseizure medications (ASMs) are the first‐line treatment for epilepsy.
Many ASMs are available; this offers the opportunity to improve therapy by tailoring it to …

Objective Optimal choice of antiseizure medication (ASM) depends on seizure type,
syndrome, age, gender, comorbidities and co‐medications. There are no fixed rules on how …

Epilepsy affects approximately 50 million people worldwide, with an annual incidence of 50
to 70 cases per 100,000 population. 1 The condition can strike at any time of life, with an …

The pharmacological treatment of epilepsy entails several critical decisions that need to be
based on an individual careful risk–benefit analysis. These include when to initiate treatment …

Objective Only 50% of patients with new‐onset epilepsy achieve seizure freedom with their
first antiseizure medication (ASM). A growing body of data illustrates the complexity of …

The advent of multiple new antiepileptic drugs (AEDs) in the past 15 years has provided new
options for clinicians treating patients with epilepsy, but has also created a need for …

Opinion statement Choosing the most appropriate treatment for a patient with epilepsy
depends on complicated and critical decisions. The number of treatment options has …

The management of patients with epilepsy is focused on three main goals: controlling
seizures, avoiding treatment side effects, and maintaining or restoring quality of life …

Introduction: There are over twenty anti-seizure medications and anti-seizure devices
available commercially in the United States. The multitude of treatment options for seizures …

Drug-resistant epilepsy occurs in 25–30% of patients. Furthermore, treatment with a first-
generation antiseizure drug (ASD) fails in 30–40% of individuals because of their intolerable …